Baseline B12 assessment should be considered before starting GLP-1/GIP therapy, particularly in patients taking metformin, following plant-based diets, or with malabsorption conditions
Circulation Population Health And Outcomes 2020, 13: e006231-e006231
This case study goes beyond content knowledge
Coverage for GLP-1 medications under an EPO may be limited to specific brands or require prior authorization
On average, patients on GLP-1 medication can lose 15% of their body weight in a year.* It is important to remember that results and timelines can vary
Avoid the inner thigh, back of the thigh, or areas very close to the knee or hip bone, as these regions have less predictable fat distribution or higher nerve concentration